cyrilzakka/clinical-trials huggingface dataset:
Experiential HIV Testing Increasing Testing Related Knowledge and Practice, and Reduce Stigma Toward HIV of Nurses.

This is a randomized controlled trial design. The investigators plan to recruit about 60 to 70 emergency department nurses from a medical center in Taipei, Taiwan. After completing the paper consent form, these nurses will be randomly assigned to 2 groups, which are a control group and an experimental group. The pre-test includes the demographic data sheet, HIV testing related knowledge and practice scale, and The Health Care Provider HIV/ AIDS Stigma Scale (HPASS). All nurses will receive a learning material when they finish the pre-test. In addition, the experimental group will be provided a real HIV testing and counselling by a researcher. The post-test will be finished one month later of pre-test in the control group, and one month later while the intervention completed in the experimental group. The semi-structural interview will be performed to the experimental group to collect and analyze their opinion toward the experiential HIV testing.

This project aims to develop an intervention of "experiential HIV testing" and to verify the following effects on emergency nurses: (1) Improve HIV testing related knowledge and practice; (2) Reduce HIV-related stigma; (3) Find out the possible demographic factors that might affect the effectiveness of experiential HIV Testing. During the intervention, nurses can directly participate in the whole process of anonymous HIV testing in the role of who need to be screened, and pre- and post-testing counselling accompanied the education and discussion will also be provided to them by a researcher. Through the above-mentioned measures, the knowledge and practices related to the HIV testing could be improved, and the stigma attitude toward HIV could be reduced through the self-reflection on the testing process.

Eligibility Criteria:
Inclusion Criteria:

- have registered nurse license and do clinical care in emergency department

Exclusion Criteria:

* have registered nurse license but doesn't do clinical care, likes head nurse.
* do clinical care in emergency department but doesn't have registered nurse license, like volunteers or assistant nurse.
* have experienced non-occupational HIV testing.
* had been a nurse in HIV/AIDS-focus ward or HIV/AIDS case manager.
Self-administered Dual-task Training for Reducing Falls Among the Older Adults

Evidence supports that dual-task training reduces fall risk among older adults. However, the current framework for preventive care for fall prevention in Hong Kong does not include formal cognitive training, while little to no emphasis is placed on combining physical and cognitive training (dual tasking) to prevent falls. Secondly, the healthcare costs for eligible Hong Kong citizens are subsidised by between 81 and 97% of the actual treatment cost. Therefore, there is a demanding need for cost-effective treatment to reduce the country's' economic burden. This project will assist policymakers and clinicians in recommending cost-effective treatments for fall prevention.

Objective: Evaluate the effectiveness and cost-effectiveness of self-administered dual-task training (sDTT) for preventing falls among older adults and promote this technique to the target population and healthcare workers of Hong Kong.

Design: In Phase 1, a multi-centre randomised controlled trial (RCT) with economic evaluation will evaluate the effectiveness and cost-effectiveness. In Phase 2, the technique will be promoted through hands-on workshops for older adults and helpers; and promotional talks with physiotherapists and rehabilitation nurses.

Setting: Community-based elderly care centres. Participants: For the RCT, we will recruit 190 community-dwelling older (≥65 years) adults of both genders having experienced at least one fall in the past 6 months. 500 community-dwelling older adults will be recruited for the workshop and 100 healthcare workers will be engaged for promotion activities.

Intervention: In Phase 1, the experimental group will receive sDTT from a physiotherapist once every 2 weeks for 12 weeks. They will perform home exercises once per week for 12 weeks. Unsupervised exercises will then continue over the next 6 months. Control group will receive the same amount of self-administered single-task training as the experimental group.

Primary outcome measure: Number of falls will be assessed at baseline (T1), post-intervention after 12 weeks (T2) and 6 months (T3). Health promotion will be assessed using a knowledge and attitude questionnaire.

Analysis: General linear mixed model with maximum likelihood estimation will compare primary and secondary outcome measures. Cost-effectiveness will be assessed from the Hong Kong healthcare perspective. Wilcoxon Signed-Rank test will assess the benefits of health promotion.

Eligibility Criteria:
Inclusion Criteria:

* Community-dwelling
* Ambulant with or without the use of a walking assistive device
* Have experienced at least one fall over the past 6 months and
* Obtained a mini-mental state examination score of ≥ 24 (indicating the absence of cognitive impairment).

Exclusion Criteria:

* Have been diagnosed with dementia or Alzheimer's disease,
* Have a previous history of psychiatric illness
* Are only able to walk with hand-held support
* Have a severe visual impairment that prevents exercise participation.
The Activity of Tissue Engineering Skin Substitutes

The main purpose of this experiment was to evaluate the activity of tissue engineering skin substitutes safety and efficacy studies for the treatment of difficult to heal wounds

This study for 6 months for a single center, open, randomized, controlled clinical trials before and after itself, test contains preliminary screening, treatment and follow-up after discharge of the patient.After treatment in patients with early debridement, in the case of no infection of living tissue engineering skin substitute transplantation, observe the wound healing after transplantation, chronic wound evaluation activity of tissue engineering skin substitutes in the efficacy and safety of wound healing after transplantation.

Eligibility Criteria:
Inclusion Criteria:

1. Meet difficult had 1 month or more to heal the wound patients
2. Who signed the informed consent of men or women older than 17 (pregnancy)
3. Has the ability to care for, has the ability to self signed informed consent, 7 to 17 years old must be signed by the guardian informed consent
4. The process of mental stability, can finish the test

Exclusion Criteria:

1. Known allergic to bovine collagen or gao min physique
2. the wound is greater than the10cm×10cm
3. People with mental illness, drug abusers and or other items
4. Pregnant women,Prepare a pregnancy or breast feeding women
5. 3 months participated in other similar experiment
6. Serious infectious disease not controller
7. With surgery, such as severe trauma stress situation
8. Can not meet the requirement of the long-term follow-up of patients
Examining the Feasibility of Implementation, Patterns of Association, and Outcomes in HRV Biofeedback (HRVB) Intervention and Music Listening Control (MLC) on Alzheimer's Disease (AD) Family Caregivers (FCGs) Public Title: Caring Relationship Expression Study

In a remotely delivered nationwide pilot study, we will be examining a novel 8-week heart rate variability biofeedback (HRVB) intervention vs music listening control (MLC) for 30 family caregivers 18 years and older (FCGs) of Alzheimer's disease (AD) (and related dementias: ADRD) patients to examine feasibility (acceptability/adherence, satisfaction) and direction of change in caregiver burden, stress, resilience, anxiety, self-compassion, and relationship quality.


Eligibility Criteria:
Inclusion Criteria:

* 18 years and above
* primary, unpaid family caregiver for ADRD patient for 6 months or more
* owns and operates a smartphone with a data plan
* greater than of equal to 4 on caregiver burden scale

Exclusion Criteria:

* regular mind-body practice
* under 18 years old
* pacemaker
* conditions or medications that interfere with heart rate variability
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer

The primary objective of the trial is to evaluate the clinical anti-tumor activity of EMD 525797 administered as 1-hour intravenous infusion every 3 weeks in terms of progression free survival (PFS) time in subjects with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (mCRPC).


Eligibility Criteria:
Inclusion Criteria:

* Histologically or cytologically confirmed adenocarcinoma of the prostate (Gleason score)
* Bisphosphonate treatment
* Stable, ongoing adequate testosterone suppression proven by hypogonadal levels of testosterone (less than or equal to) \<= 50 nanogram per deciliter \[ng/dL\]) for subjects without surgical castration (luteinizing hormone-releasing hormone antagonists and agonists)
* Other protocol defined inclusion criteria could apply

Exclusion Criteria:

* Prior chemotherapy, biologic therapy (targeted therapy), or any experimental therapy for mCRPC
* Chronic and ongoing treatment with opioids
* Acute pathologic fracture, spinal cord compression, or hypercalcemia at Screening
* Visceral metastasis, brain metastasis
* Radiotherapy to bone lesions and/or orthopedic surgery for pathologic fractures. Any kinds of major elective surgery within 30 days prior to trial treatment
* Other protocol defined exclusion criteria could apply
A Study of Wearable Devices to Predict Migraines

The purpose of this research is to determine if data from smart devices, including heart rate and movement during sleep and wake times, will be able to track headaches and predict recurrence and exacerbations (make worse). This use of this information may in the future allow patients earlier and more effective treatments if these devices can help predict when the headaches may occur.


Eligibility Criteria:
Inclusion Criteria:

* Age 18 years and older (no upper age limit defined)
* History of chronic migraine as defined by the International Headache Society's International Classification of Headache Disorders (3rd edition).
* Response to current preventative therapy with ≥ 50% improvement in the frequency of headache days when compared to baseline
* 4 to 14 average number of total headache days per month during peak efficacy of preventative therapy
* Ability to understand study procedures and to comply with them for the entire length of the study and use study devices as outlined in protocol.
* Patient agrees to maintain a daily electronic headache diary.
* Proficient in the use of electronic devices including Apple HomeKit and Apple Watch. - Subjects owns an iPhone with iOS 16 or later operating system installed on iPhone. Apple watch series 8 with watch OS6 or later will be provided by the study.

Exclusion Criteria:

* Chronic daily headache with no periods of headache freedom.
* ≥ 15 average number of headaches days per month during peak efficacy of preventative treatment.
* Medication overuse headache as defined by the International Headache Society's International Classification of Headache Disorders (3rd edition).
* Daily opioid use for \> 3 months (e.g., hydrocodone, oxycodone, fentanyl patch) or other daily analgesic use for chronic pain disorders (e.g., NSAIDS or acetaminophen).
* Inability or unwillingness of individual or legal guardian/representative to give written informed consent.
Patient Perception of Mammogram Guidelines

The purpose of this study was to determine attitudes regarding the 2009 USPSTF Guidelines for breast cancer screening for women in their 40's and assess the effect of one of two newspaper articles on their attitudes. The population studied was women seeing their private gynecologist for annual exams in the 39-49 year old age group.

Subjects completed a baseline questionnaire listing demographics, previous experience with mammograms, and acquaintances with breast cancer. They then were randomly assigned one of two articles (one favorable and one unfavorable) that had been published in the newspaper regarding the USPSTF breast cancer screening guidelines. Their attitudes towards the safety of the guidelines and their willingness to comply with them was then measured.

Eligibility Criteria:
Inclusion Criteria:

* women aged 39-49 seeing their gynecologist for routine preventive care

Exclusion Criteria:

* women not aged 39-49
* women with breast cancer
* women not able to read English
Do Childhood Measles and DTaP Vaccination Decrease the Mortality Rate Caused by COVID-19 in OECD Countries?

Mortality rates caused by SARS CoV-2 differ between countries and this difference might be explained by several reasons. Childhood vaccination rate is thought to be one of them. Therefore present study aimed to examine the possible relationship between DTaP (diphtheria, tetanus, pertussis) and measles vaccination rates of Organization for Economic Co-operation and Development (OECD) countries and case fatality rate (CFR) caused by SARS CoV-2.

The mortality rates caused by SARS CoV-2 differ between countries and this difference might be explained by several reasons. Childhood vaccination rate is thought to be one of them. Therefore present study aimed to examine the possible relationship between DTaP (diphtheria, tetanus, pertussis) and measles vaccination rates of Organization for Economic Co-operation and Development (OECD) countries and case fatality rate (CFR) caused by SARS CoV-2.A total of 32 OECD countries, of northern hemisphere, have been included in this study. Statistical analysis performed according to the CFR data of these countries based on SARS CoV-2. The CFR data calculated according to the total mortality count of a specific country for the 3-month period down from the date when first SARS CoV-2 case was observed.

Eligibility Criteria:
Inclusion Criteria:

* Children vaccinated in OECD countries in northern hemisphere

Exclusion Criteria:

* Non vaccinated children
* Southern hemisphere countries
* non-OECD countries
Effect of Perioperative Oral Pregabalin in Total Knee Replacement

This interventional randomized control trial aim to determine efficacy and safety of Oral pregabalin in improving after surgery pain control in patients undergoing total knee replacement surgeries under regional anesthesia. We'll compare the efficacy of pregabalin between two groups, pregabalin group and control group on the basis of their opioid consumption after knee operation.

After obtaining approval from the institutional ethical committee and informed written consent, 120 patients fulfilling the inclusion criteria will be included in this study. The patients will be randomly assigned into two equal groups; Group P: Pregabalin group and Group C: control group. Group P will receive oral capsule pregabalin 75mg one hour preoperatively and Group C will not receive any premedication preoperatively.

Intraoperatively both groups will receive inj. Midazolam 2 mg before subarachnoid block with hyperbaric Bupivacaine 0.5% 2.5-3ml and fentanyl 15mcg in the operation theatre (OT). Both groups will also receive parecoxib 40mg IV and paracetamol 1G Intravenous (IV) as part of multimodal analgesia. Both groups will receive dexamethasone 8mg IV prophylactically.

Postoperatively both groups will receive Ultrasound guided Adductor canal saphenous Nerve block in the PACU with 0.2% Bupivacaine 20-30ml \& dexmeditomidine1.0mcg/kg. Group P will receive oral capsule pregabalin 75 mg Q12hourly from the 1st dose for next 60 hours. Group C will not receive any medication. Both groups will receive paracetamol 1G IV Q6Hourly and Rescue Analgesia will be provided with oral oxycodone 5mg TDS and Morphine PCA, in escalating manner as per patient requirement.

for 24 hrs. After 24 hours Both groups with receive tab paracetamol1 g Q4hourly, ibuprofen 400 Q8hourly along with Tab oxycodone as PRN Q8Hourly and PCA morphine.

Eligibility Criteria:
Inclusion Criteria:

1. Age between 18 to 85 year
2. Elective Regional anesthesia.
3. Able to follow study protocol

Exclusion Criteria:

1. ASA -IV
2. Age \<18 \& \> 85 years
3. Patients on pregabalin for chronic neuropathic pain.
4. Patient under General anesthesia
5. Patients with chronic liver failure
6. Patients with chronic renal failure on Hemodialysis
7. Patients on opioid (\>3 month)
8. Patient with complicated knee surgery
Lidocaine on Early Cognitive Dysfunction in Shoulder Arthroscopy

The beach chair position (BCP) combined with deliberate hypotension impair cerebral perfusion pressure and oxygenation during arthroscopic shoulder surgeries and produce cerebral ischemia.

Arthroscopic diagnosis and treatment of shoulder disorders have replaced open procedure as the primary treatment method. The beach chair (BCP) and lateral decubitus (LDP) positions are both considered as reliable techniques for performing effective arthroscopic shoulder surgeries. The usage of BCP for shoulder arthroscopic operations started from early 1980s.

The advantages of BCP include lack of brachial plexus strain, good intra-articular visualization, with the ease of conversion to an open approach if required.

The BCP combined with deliberate hypotension has been used to decrease intraoperative blood loss and allow a relatively blood-free surgical field. However, this combination has the risk to impair cerebral perfusion pressure and oxygenation during surgery and produce cerebral ischemia.

Lidocaine, a commonly used local anesthetic and class IB antiarrhythmic drug, that readily crosses the blood - brain barrier. Evans et al. initially reported cerebral protection of lidocaine in a feline model of cerebral arterial gas embolism. Later on, the effects of lidocaine on perioperative neuroprotection were detected. However, the mechanisms underlying lidocaine treatment-induced neuroprotection remain incompletely understood.

Lidocaine may provide cerebral protection through many mechanisms, including decreasing the cerebral metabolic rate, decelerating the ischemic transmembrane ion shift, and reducing the ischemic excitotoxin release.

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing elective arthroscopic shoulder surgery under general anesthesia in beach chair position (BCP),
* Age 20 to 65 years old.

Exclusion Criteria:

* Mini-Mental State Examination (MMSE) score \< 23 before surgery
* History of neurological disease (such as previous episodes of cerebral ischemia or stroke).
* History of psychological disorder
* Suspected history of adverse reactions to lidocaine
* Drug or alcohol abuse
* History of diabetes mellitus, sever hypertension, severe anemia, hepatic or renal dysfunction
* Unwillingness to comply with protocol.
Rifaximin in Patients With Diabetic Gastroparesis

Researchers are trying to determine if subjects with diabetic gastroparesis and symptoms of bloating will have a greater improvement in bloating symptoms when treated with rifaximin.


Eligibility Criteria:
Inclusion Criteria

* Men and women adult patients, aged 18-75, with diabetic gastroparesis
* Diagnosis of diabetic gastroparesis will have been made previously using a combination of symptoms (e.g., nausea, vomiting, bloating, early satiety, abdominal pain), the absence of mechanical obstruction, and delayed gastric emptying using a 4-hour, solid phase scintigraphic study (GES; \> 20% remaining at 4 hours)

Exclusion Criteria

* Prior surgery to the stomach or esophagus
* Known mechanical obstruction of the GI tract
* Current or recent (\< 4 weeks) use of opioids
* Current/active use of cannabis
* Current or recent (\< 4 weeks) use of antibiotics
* Current or recent use of antifungal agents (\< 4 weeks)
* Prior treatment with rifaximin (\< 1 year)
* Uncontrolled diabetes with a HgbA1c \> 12
* Severe uncontrolled or untreated anxiety or depression.
Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting

Test the safety, immune response and efficacy of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 compared to chemotherapy or CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma


Eligibility Criteria:
Inclusion Criteria:

* Have histologically proven malignant adenocarcinoma of the pancreas; measurable disease is not required, mixed histology is not allowed; subjects must have metastatic disease
* 2nd line, 3rd line or greater
* At least 18 years of age
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
* Anticipated life expectancy \>12 weeks
* For women and men of childbearing potential, a medically acceptable method of highly effective contraception (oral hormonal contraceptive, condom plus spermicide, or hormone implants) must be used throughout the study period and for 28 days after their final vaccine administration. A barrier method of contraception must be employed by all subjects (male and female), regardless of other methods.
* Have adequate organ function as defined by specified laboratory values

Exclusion Criteria:

* Allergy to both penicillin \& sulfa or suspected hypersensitivity to granulocyte-macrophage colony stimulating factor (GM-CSF), dimethyl sulfoxide, fetal bovine serum, trypsin, yeast, glycerol or other component of the therapy options
* Known history or evidence of brain metastases, immunodeficiency disease or immunocompromised state or history of autoimmune disease requiring systemic steroids or other immunosuppressive treatment
* Have any evidence of hepatic cirrhosis or clinical or radiographic ascites
* Have prosthetic heart valves, major implant or device placed in the last 12 months or history of infection with implant/device that cannot be easily removed
* Rapidly progressing disease
* Clinically significant and/or malignant pleural effusion
* Received prior GVAX pancreas vaccine or CRS-207
* Major surgery or significant traumatic injury (or unhealed surgical wounds) occurring within 28 days prior to receiving study drug, or planned surgery requiring general anesthesia
* Infection with HIV or hepatitis B or C at screening
* Valvular heart disease that requires antibiotic prophylaxis for prevention of endocarditis
* Pregnant or breastfeeding
* Unable to avoid close contact with another individual known to be at high risk of listeriosis (e.g., newborn infant, pregnant woman, HIV-positive individual) during the course of CRS-207 treatment until completion of antibiotic regimen
* Conditions, including alcohol or drug dependence, intercurrent illness, or lack of sufficient peripheral venous access, that would affect the patient's ability to comply with study visits and procedures